Abbvie CDR (ABBV) Börsenkurse

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products PR Newswire IRVINE, Calif., Nov. 18, 2024 Seven new e-trainings...

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer PR Newswire NORTH CHICAGO, Ill., Nov. 18, 2024 ELAHERE...

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations PR Newswire NORTH CHICAGO, Ill., Nov. 14, 2024 AbbVie Migraine Career Catalyst Award™ contest winners shared...

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia PR Newswire NORTH CHICAGO, Ill., Nov. 11, 2024 EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their...

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day PR Newswire IRVINE, Calif., Nov. 7, 2024 Last Year, BOTOX® Cosmetic Day Set the Record for the Most BOTOX® Cosmetic...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation...

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics PR Newswire NORTH CHICAGO, Ill. and BRANFORD, Conn...